Oct 23 (Reuters) - Pathos AI said on Friday it had entered into a collaboration with Bristol Myers Squibb and Tempus AI to ...

ChatGPT maker OpenAI is folding Orchestra’s drug-program agents into Rosalind, its life sciences suite of products.

AI delivers potent and selective ATR inhibition, CNS-oriented properties and preclinical tumour-growth control, advancing a capital-efficient drug discovery program toward candidate selection ...

Tempus to build a de-identified dataset from hundreds of thousands of patients with neurological conditions; Pathos to ...

Pathos AI Inc. today announced that it has raised $237 million in funding at a $3 billion valuation. Pharmaceutical giant ...

As artificial intelligence (AI) permeates more fields and applications, organizations may find that it proves difficult to wield without the right knowledge and skill set. That’s why software ...

These questions over whether AI belongs in the classroom is so polarizing that we cannot put this burden solely on the ...

The Living Laboratory was announced on Oct. 6 as a network where researchers and educators can collaborate to shape the ...

Rocket One Inc. ("Rocket One" or the "Company") today announced a sponsored research agreement with Virginia Commonwealth University ("VCU") to develop and demonstrate magnetic computing devices ...

More than 1,000 employees at America’s leading AI companies, including senior staff members and some co-founders at OpenAI, Anthropic and Google DeepMind, signed a statement asking the U.S. government ...